Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 308,636 | 401,590 | 397,433 | 453,932 | 331,696 |
| Receivables | 511,250 | 533,606 | 507,208 | 457,445 | 452,699 |
| Inventories | 389,804 | 379,958 | 390,599 | 380,282 | 393,974 |
| Other current assets | 224,054 | 213,458 | 206,733 | 203,595 | 205,861 |
| TOTAL | $1,433,744 | $1,528,612 | $1,501,973 | $1,495,254 | $1,384,230 |
| Non-Current Assets | |||||
| PPE Net | 717,745 | 708,178 | 708,725 | 702,177 | 687,101 |
| Intangibles | 518,956 | 518,833 | 524,024 | 450,461 | 448,895 |
| Other Non-Current Assets | 680,321 | 659,244 | 618,793 | 612,033 | 566,178 |
| TOTAL | $1,917,022 | $1,886,255 | $1,851,542 | $1,764,671 | $1,702,174 |
| Total Assets | $3,350,766 | $3,414,867 | $3,353,515 | $3,259,925 | $3,086,404 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 99,140 | 170,112 | 74,998 | 74,997 | 149,990 |
| Accounts payable and accrued liabilities | 110,603 | 117,468 | 117,462 | 110,643 | 112,609 |
| Accrued Expenses | 511,047 | 541,124 | 476,249 | 478,712 | 420,312 |
| TOTAL | $1,009,224 | $1,116,702 | $956,902 | $951,547 | $970,193 |
| Non-Current Liabilities | |||||
| Long Term Debt | 524,758 | 524,743 | 620,778 | 622,883 | 618,813 |
| Deferred Revenues | 38,434 | 37,998 | 38,193 | 37,195 | 37,282 |
| Other Non-Current Liabilities | 166,299 | 156,361 | 170,140 | 165,197 | 161,681 |
| TOTAL | $723,488 | $717,912 | $827,707 | $823,848 | $818,804 |
| Total Liabilities | $1,732,712 | $1,834,614 | $1,784,609 | $1,775,395 | $1,788,997 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 81,885 | 82,306 | 82,587 | 83,089 | 83,052 |
| Common Shares | 10,770 | 10,769 | 10,767 | 10,751 | 10,745 |
| Retained earnings | 5,116,289 | 4,883,448 | 4,680,150 | 4,444,571 | 4,250,050 |
| Other shareholders' equity | -70,368 | -79,415 | -74,760 | -65,357 | -69,412 |
| TOTAL | $1,618,054 | $1,580,253 | $1,568,906 | $1,484,530 | $1,297,407 |
| Total Liabilities And Equity | $3,350,766 | $3,414,867 | $3,353,515 | $3,259,925 | $3,086,404 |